The advance of the third‑generation EGFR‑TKI in the treatment of non‑small cell lung cancer (Review).

ABSTRACT: Lung cancer is currently the second most common type of cancer with the second incidence rate and the first mortality rate worldwide. Non‑small cell lung cancer (NSCLC) accounts for ~85% of the total number of cases of lung cancers. Concerning the treatment of NSCLC, targeted therapy has become a research hotspot in recent years because of its favorable efficacy, high selectivity and minimal adverse reactions. Among the drugs used in targeted therapy, the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are the most common and are categorized into four generations. The use of first and second‑generation drugs leads to drug resistance within 8‑14 months. This resistance is primarily caused by the T790M mutation, which is the most observed mechanism. A third‑generati

SUBMITTER: Cheng Z 

PROVIDER: S-EPMC10739988 | biostudies-literature | 2024 Jan

REPOSITORIES: biostudies-literature